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Different Impact of Diabetes Mellitus on In-hospital    
and 1-Year Mortality in Patients with Acute Myocardial    
Infarction Who Underwent Successful Percutaneous    
Coronary Intervention: Results from the Korean Acute  
Myocardial Infarction Registry
Keun-Ho Park, Youngkeun Ahn, Myung Ho Jeong, Shung Chull Chae, Seung Ho Hur, Young Jo Kim, 
In Whan Seong, Jei Keon Chae, Taek Jong Hong, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, 
Yang Soo Jang, and Korean Acute Myocardial Infarction Registry Investigators
Cardiovascular Center, Chonnam National University Hospital, Gwangju, Korea
Background/Aims: The aim of this study was to evaluate the impact of diabetes mellitus (DM) on in-hospital and 1-year 
mortality in patients who suffered acute myocardial infarction (AMI) and underwent successful percutaneous coronary 
intervention (PCI). 
Methods: Among 5,074 consecutive patients from the Korea AMI Registry with successful revascularization between 
November 2005 and June 2007, 1,412 patients had a history of DM. 
Results: The DM group had a higher mean age prevalence of history of hypertension, dyslipidemia, ischemic heart 
disease, high Killip class, and diagnoses as non-ST elevation MI than the non-DM group. Left ventricular ejection 
fraction (LVEF) and creatinine clearance were lower in the DM group, which also had a significantly higher incidence 
of in-hospital and 1-year mortality of hospital survivors (4.6% vs. 2.8%, p = 0.002; 5.0% vs. 2.5%, p < 0.001). A 
multivariate analysis revealed that independent predictors of in-hospital mortality were Killip class IV or III at admission, 
use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers, LVEF, creatinine clearance, and 
a diagnosis of ST-elevated MI but not DM. However, a multivariate Cox regression analysis showed that DM was an 
independent predictor of 1-year mortality (hazard ratio, 1.504; 95% confidence interval, 1.032 to 2.191).
Conclusions: DM has a higher association with 1-year mortality than in-hospital mortality in patients with AMI who 
underwent successful PCI. Therefore, even when patients with AMI and DM undergo successful PCI, they may require 
further intensive treatment and continuous attention.
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INTRODUCTION
Acute myocardial infarction (AMI) remains a leading 
cause of morbidity and mortality worldwide. However, 
mortality from MI has decreased over the years due to 
improvements in percutaneous coronary intervention Park KH, et al. Impact of DM on mortality in AMI   181
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(PCI) techniques and the development of stents, new 
life-saving devices, and medications. Nevertheless, 
many clinical risk factors affect high mortality in pa-
tients with AMI. 
Diabetes mellitus (DM) is well-known as a coronary 
artery equivalent disease and a major cardiovascular 
risk factor [1]. Patients with DM have a higher rate of 
AMI and a greater need for repeated revascularization 
after PCI [2,3]. After suffering from AMI, short- and 
long-term mortality rates are twice as high for patients 
with DM as those without DM [4,5]. However, in the 
recently improved interventional era of drug-eluting 
stents, few large-scale studies have been reported about 
the impact of DM on clinical outcomes, particularly in 
patients with AMI who underwent successful PCI. 
In the present study, we compared in-hospital and 
1-year mortality in diabetic and non-diabetic patients 
with AMI who underwent successful PCI using data 
from the Korean Acute Myocardial Infarction Registry 
(KAMIR). 
METHODS
Study design and patient population
We consecutively selected 5,074 patients with AMI 
who underwent successful PCI from November 2005 to 
June 2007 and had 1-year follow-up data in the KAMIR. 
Among them, patients with a history of DM, regardless 
of whether they received treatment, were assigned to 
the DM group (n = 1,412) and those without a history of 
DM were assigned to the non-DM group (n = 3,662).
The KAMIR is a prospective, multicenter, observa-
tional, online registry that can be used to evaluate epi-
demiology, current management, and clinical outcomes 
in Korean patients with AMI and improve care for AMI 
patients. Data, including baseline clinical and angio-
graphic characteristics as well as clinical outcomes, 
were collected by a specialized study coordinator at 
each center using a standardized case report form. AMI 
was diagnosed by characteristic clinical presentation, 
serial changes on electrocardiogram (ECG) suggesting 
infarction, and increases in cardiac enzymes [6]. The 
diagnosis of ST-segment elevated myocardial infarction 
(STEMI) was based on a suggestive history with an ST 
elevation of 2 mm in two precordial leads, an ST eleva-
tion of 1 mm in two limb leads, or a new left branch 
bundle block on 12-lead ECG with a concomitant in-
crease in troponin-I or -T to the 99th percentile of the 
upper reference limit.
Procedural and post-intervention medications
Emergent or early invasive treatments were deter-
mined based on the status of the patients with AMI 
according to the clinical decision of the operators. Pri-
mary PCI was defined as angioplasty and/or stenting 
as quickly as possible in patients with STEMI. Early 
invasive treatment was defined as angioplasty and/or 
stenting within 24 hours of admission in patients with 
non-STEMI. Coronary angiography was performed by 
transfemoral or transradial approaches. Conventional 
heparin was infused during the procedure to maintain 
an activated clotting time of at least 250 seconds. Stents 
were implanted in cases in which significant coronary 
artery stenosis was present following balloon angio-
plasty. The type of stent was decided by the operator. 
Successful revascularization was defined as a target 
vessel at the treatment site that had achieved angio-
graphic residual stenosis of < 30% following balloon 
angioplasty or implantation of stents in the presence of 
thrombolysis in myocardial infarction (TIMI) antegrade 
3 flow. Antiplatelet agents were administered to all pa-
tients prior to intervention, including 300 mg aspirin 
and 300-600 mg clopidogrel. After the intervention, 
100 mg aspirin was recommended as a treatment for 
life and 75 mg clopidogrel was administered for at least 
1 year. Other medical treatments, including angiotensin 
converting enzyme inhibitors (ACEis) or angiotensin II 
receptor blockers (ARBs), beta-blockers, calcium chan-
nel blockers, and lipid-lowering agents were also used 
based on the standard treatment regimen for patients 
with AMI according to the physician’s decision.
Study endpoints and definition
The primary endpoint was in-hospital and 1-year 
mortality of patients with AMI with and without DM. 
The secondary endpoint was 1-year major adverse 
cardiac events (MACE) defined as the composite of 
cardiac death, nonfatal MI, target lesion revasculariza-
tion (TLR), target vessel revascularization (TVR), and 
coronary artery bypass graft. Cardiac death was defined 
as any death with an undetermined cause and a defini-182    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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tive noncardiac origin. TLR or TVR was defined as any 
percutaneous coronary revascularization performed on 
a treated lesion or vessel. Hypertension was defined as 
a history of hypertension or antihypertensive medica-
tion use. A current smoker was defined as someone who 
reported smoking cigarettes during the past 30 days. 
Dyslipidemia was defined as a diagnosis previously 
made by a physician or treatment with lipid-lowering 
medications. Baseline creatinine clearance was calcu-
lated using the Cockcroft-Gault formula considering 
age, gender, and body weight.
Statistical analysis
Continuous variables are expressed as mean ± SD, 
and categorical variables are expressed as frequencies. 
The analysis of continuous variables was performed 
using Student’s t test and that of categorical variables 
was performed using the chi-square or Fisher’s exact 
tests. Multiple logistic regression and Cox proportional 
regression analyses were conducted to identify the in-
dependent predictors of in-hospital and 1-year mortal-
ity. Variables entered into the multivariate models were 
age, gender, creatinine clearance, history of hyperten-
sion, DM, dyslipidemia, ischemic heart disease, current 
smoker, left ventricular ejection fraction (LVEF), ACC/
AHA B2 or C lesions, Killip class on admission, mul-
tivessel disease, STEMI or non-STEMI, concomitant 
medications, and stent type. All statistical analyses 
were performed using SPSS version 15.0 (SPSS Inc., 
Chicago, IL, USA). All statistical tests were two-tailed, 
and a p value < 0.05 was considered statistically signifi-
cant.
RESULTS
Baseline characteristics
Mean age was higher in the DM group than in the 
non-DM group. Female gender, history of hyperten-
sion, dyslipidemia, previous ischemic heart disease, and 
diagnosis of non-STEMI were more prevalent in the 
DM group. However, male gender, current smoker, and 
diagnosis of STEMI were more prevalent in the non-
DM group. LVEF and creatinine clearance were lower in 
the DM group. However, no differences in concomitant 
medications except calcium channel blockers were ob-
served between the two groups. Table 1 shows the base-
line clinical characteristics, concomitant medications, 
and laboratory findings of the two groups. 
In the baseline angiographic and procedural charac-
teristics, single-vessel disease was more prevalent in the 
non-DM group than in the DM group. However, three-
vessel disease or left main coronary artery disease were 
more prevalent in the DM group, whereas preproce-
dural TIMI antegrade 0 flow rates were more common 
in the non-DM group and postprocedural TIMI ante-
grade flow rates did not differ between the two groups. 
TAXUS stents (Boston Scientific Co., Natick, MA, 
USA) were used more commonly in the non-DM group, 
whereas Cypher stents (Cordis, Johnson & Johnson, Mi-
ami Lakes, FL, USA) were used more commonly in the 
DM group. The stent diameter of the target lesion was 
smaller, and the total number of implanted stents was 
more numerous, in the DM group than in the non-DM 
group (Table 2).
Clinical outcomes
The DM group had a significantly higher incidence of 
in-hospital mortality than the non-DM group (4.6% vs. 
2.8%, p = 0.002). 
Approximately 92% of all hospital survivors were 
available for the 1-year clinical follow-up, during which 
the DM group had significantly higher incidences of to-
tal mortality (5.0% vs. 2.5%, p < 0.001), cardiac death 
(3.4% vs. 1.4%, p < 0.001), and MACE (12.0% vs. 8.7%, p 
= 0.001) than did the non-DM group (Table 3).
Subgroup analyses showed that the incidence of in-
hospital mortality in the DM group was significantly 
higher than in non-DM patients with STEMI (6.2% vs. 
3.5%, p = 0.001), but no difference in in-hospital mor-
tality was observed between the two groups in patients 
with non-STEMI (2.4% vs. 1.6%, p = 0.164). However, 
the incidence of 1-year mortality in the DM group was 
higher than that of non-DM patients with both STEMI 
and non-STEMI (4.6% vs. 2.7%, p = 0.010 in STEMI; 
5.5% vs. 2.1%, p < 0.001 in non-STEMI).
A Kaplan-Meier survival analysis revealed that the DM 
group had significantly lower 1-year survival rates than 
the non-DM group (95.2% vs. 97.7%, p < 0.001) (Fig. 1). 
Multivariate analyses
The independent predictors of in-hospital mortality Park KH, et al. Impact of DM on mortality in AMI   183
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Table 1. Baseline clinical characteristics, concomitant medications, and laboratory findings in the groups
DM group
(n = 1,412)
Non-DM group
(n = 3,662)
p value
Age, yr     63.4 ± 11.07 61.8 ± 12.76 < 0.001
Male gender 927 (65.7) 2,739 (74.8) < 0.001
Hypertension 870 (61.6) 1,556 (42.5) < 0.001
Dyslipidemia 167 (11.8)    288 (7.9) < 0.001
Current smoker 529 (37.5) 1,735 (47.4) < 0.001
Previous ischemic heart disease 237 (16.8)    468 (12.8) < 0.001
Killip class at admission < 0.001
I      996 (72.0) 2,871 (79.9)
II      199 (14.4)    424 (11.8)
III      125 (9.0)    178 (5.0)
IV        64 (4.6)     119 (3.3)
Left ventricular ejection fraction, %    50.5 ± 12.55   52.5 ± 12.06 < 0.001
Left ventricular ejection fraction < 50%      578 (44.2) 1,352 (39.5)    0.004
Creatinine clearance, mL/min    66.8 ± 39.48    73.6 ± 46.38 < 0.001
Creatinine clearance < 60 mL/min      601 (45.0) 1,236 (35.3) < 0.001
Diagnosis < 0.001
ST elevation myocardial infarction      829 (58.7) 2,421 (66.1)
Non-ST elevation myocardial infarction      583 (41.3) 1,241 (33.9)
Concomitant medication
Aspirin   1,397 (98.9) 3,638 (99.3) 0.137
Clopidogrel   1,395 (98.8) 3,635 (99.3) 0.108
ACE inhibitor or ARB    1,172 (83.0) 3,008 (82.1) 0.470
Beta-blocker   1,053 (74.6)   2,724 (74.4) 0.890
Calcium channel blocker      190 (13.5)     371 (10.1) 0.001
Lipid lowering agents   1,093 (77.4) 2,864 (78.2) 0.537
Laboratory findings on admission
Glucose, mg/dL  229.9 ± 98.99  145.2 ± 52.27 < 0.001
Maximum CK-MB, U/L  119.2 ± 245.93  163.6 ± 285.85 < 0.001
Maximum troponin-I, ng/mL      43.7 ± 76.74    52.5 ± 102.07    0.002
Maximum troponin-T, ng/mL      8.4 ± 61.10     5.7 ± 9.57    0.308
Total cholesterol, mg/dL    179.5 ± 50.10  186.8 ± 43.24 < 0.001
LDL-cholesterol, mg/dL   114.0 ± 48.00  120.8 ± 39.34 < 0.001
HDL-cholesterol, mg/dL      44.1 ± 33.27    45.9 ± 22.60    0.041
Triglyceride, mg/dL  138.0 ± 113.71  125.7 ± 98.12    0.001
BNP, pg/mL    916.9 ± 2,901.19  641.4 ± 2,648.67    0.175
N-terminal pro BNP, pg/mL  3,460.7 ± 7,604.39  1,749.3 ± 4,586.90 < 0.001
hs-CRP, mg/dL    18.5 ± 73.91    13.7 ± 59.78    0.045
Values are presented as mean ± SD or number (%).
DM, diabetes mellitus; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CK-MB, creatinine kinase MB isoen-
zyme; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BNP, brain-type natriuretic peptide; hs-CRP, high sensitivity C-reac-
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by multiple logistic regression analysis were Killip III 
or IV class on admission, use of ACEis or ARBs, LVEF, 
creatinine clearance, and STEMI, whereas DM was not 
an independent predictor of in-hospital mortality (haz-
ard ratio, 1.386; 95% confidence interval, 0.810 to 2.374; 
p = 0.234). However, independent predictors of 1-year 
mortality included Killip class on admission, age, LVEF, 
creatinine clearance, balloon angioplasty, use of bare 
metal stents, multivessel disease, female gender, cur-
rent smoker, and history of DM (Table 4).
DISCUSSION
We evaluated the impact of DM on in-hospital and 
1-year mortality in patients with AMI who underwent 
successful revascularization, and the results suggest 
that despite successful revascularization, the incidence 
of in-hospital and 1-year mortality in patients with AMI 
and DM remained high. However, DM was not an inde-
pendent predictor of in-hospital mortality, whereas DM 
was a predictor of 1-year mortality in the multivariate 
analyses.
In our cohort, patients with DM had worse baseline 
Table 2. Coronary angiographic findings and procedural characteristics in the groups
DM group
(n = 1,412)
Non-DM group
(n = 3,662)
p value
Target lesion
Left anterior descending artery  660 (46.7)  1,785 (48.7)  0.201 
Left circumflex artery  220 (15.6)     606 (16.5)  0.403 
Right coronary artery  496 (35.1)  1,213 (33.1)  0.176 
Left main   35 (2.5)       55 (1.5)  0.018 
Diseased vessels
Single vessel disease 483 (34.2)  1,741 (47.6)  < 0.001 
Two vessel disease 459 (32.5) 1,104 (30.1)       0.103 
Three vessel disease   411 (29.1)     730 (19.9)  < 0.001 
Left main disease    58 (4.1)       81 (2.2)  < 0.001 
ACC/AHA lesion classification    0.674
A or B1 357 (25.3)    905 (24.7)
B2 or C  1,055 (74.7) 2,757 (75.3)
Pre-procedural TIMI flow grade 
0  532 (37.7) 1,645 (44.9)  < 0.001 
I  158 (11.2)     333 (9.1)  0.024 
II  244 (17.3)     567 (15.5))  0.117 
III  472 (33.4)  1,099 (30.0)  0.018 
Type of stent used 0.009
TAXUS 445 (31.5) 1,275 (34.8)
Cypher 654 (46.3) 1,548 (42.3)
Other drug-eluting stents 145 (10.3)    401 (11.0)
Bare metal stents   96 (6.8)    297 (8.1)
Only balloon angioplasty   72 (5.1)    141 (3.9)
Stent diameter of target lesion, mm 3.1 ± 0.39     3.2 ± 0.41  < 0.001
Stent length of target lesion, mm  25. 3 ± 6.29   25.3 ± 6.16     0.832
Total no. of stents 1.6 ± 0.91     1.5 ± 0.82  < 0.001 
Values are presented as mean ± SD or number (%).
DM, diabetes mellitus; ACC/AHA, American College of Cardiology/American Heart Association; TIMI, thrombolysis in myocardial infarc-
tion.Park KH, et al. Impact of DM on mortality in AMI   185
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clinical characteristics than those without DM. In addi-
tion, they were more likely to have developed a worsen-
ing of Killip class at admission and a higher incidence 
of pump failure, because increased incidence of silent 
myocardial ischemia and infarction in patients with DM 
tends to lead to late presentation for medical attention 
and subsequent delayed initiation of treatment [7]. Sev-
eral studies have found that patients with AMI and DM 
have a higher incidence of in-hospital mortality than 
those without DM [8-12]. However, almost all of these 
studies included patients who received only pharma-
cological treatment for AMI. Successful revasculariza-
tion via a catheter-based approach minimizes ischemic 
injury of the myocardium and improves survival rates. 
Therefore, we included patients with AMI who under-
Table 3. In-hospital and 1-year clinical outcomes in the groups
DM group
(n = 1,412)
Non-DM group
(n = 3,662)
p value
In-hospital mortality 65 (4.6) 104 (2.8) 0.002
6-mon follow-up n = 1,343 n = 3,551
   Mortality 47 (3.5)   62 (1.7) < 0.001
      Cardiac death  33 (2.5)   38 (1.1) < 0.001
      Non-cardiac death  14 (1.0)   24 (0.7) 0.192
   Non-fatal AMI  12 (0.9)   15 (0.4) 0.047
   CABG    2 (0.1)     7 (0.2) 1.000
   Repeated PCI 75 (5.6) 170 (4.8) 0.254
      TLR 67 (5.0) 147 (4.1) 0.195
      TVR 67 (5.0) 148 (4.2) 0.211
      Non-target PCI   8 (0.6)   22 (0.6) 0.924
   MACE  120 (8.9) 227 (6.4) 0.002
12-mon follow-up n = 1,290 n = 3,400
   Mortality 64 (5.0)   85 (2.5) < 0.001
       Cardiac death  44 (3.4)   49 (1.4) < 0.001
       Non-cardiac death  20 (1.6)   36 (1.1) 0.166
   Non-fatal AMI  14 (1.1)   24 (0.7) 0.196
   CABG   3 (0.2)   12 (0.4) 0.773
   Repeated PCI  105 (8.1) 224 (6.6) 0.063
      TLR 77 (6.0) 166 (4.9) 0.134
      TVR 81 (6.3) 179 (5.3) 0.175
      Non-target PCI 24 (1.9)   45 (1.3) 0.173
   MACE  155 (12.0) 295 (8.7) 0.001
Values are presented as number (%).
DM, diabetes mellitus; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; 
TLR, target lesion revascularization; TVR, target vessel revascularization; MACE, major adverse cardiovascular events.
Figure 1. Kaplan-Meier curves for all-cause mortality in the 
groups. DM, diabetes mellitus.
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went successful revascularization and excluded patients 
with AMI who received only medical treatment or 
thrombolytic therapy without mechanical revascular-
ization. 
Our results showed that despite successful revascu-
larization in patients with AMI, patients with DM still 
had a higher incidence of in-hospital mortality than 
those without DM. Other trials have reported that a 
significant delay from symptom onset to hospital arrival 
in patients with DM results in a significant delay in re-
perfusion treatment [7,13,14]. The presenting symptoms 
of patients with DM may also be more difficult to relate 
to active ischemic heart disease and may be associated 
with a delay in the AMI diagnosis. Delayed treatments 
were associated with poor clinical outcomes during the 
hospital stay.
Patients with DM have increased platelet aggrega-
tory and procoagulant activity, leading to an inher-
ently greater incidence and rate of thrombus formation 
[13,15]. However, our results showed that patients with 
DM had a lower incidence of pre-procedural TIMI an-
tegrade 0 or 1 flow than those without DM. This find-
ing may be based on patient selection bias, because we 
included patients who underwent successful revascu-
larization. However, despite better preprocedural TIMI 
flow, patients with DM had poorer in-hospital outcomes. 
This is also evidence of the negative impact of DM on 
AMI. 
DM was not an independent predictor of in-hospital 
mortality, which has been reported in other trials 
[8,9,12]. Independent predictors of in-hospital mortal-
ity were high Killip class on admission, use of ACE is or 
ARBs, depressed LVEF, decreased renal function, and 
STEMI. Successful PCI could probably improve in-hos-
pital survival rates and influence the predictors of in-
hospital mortality. Therefore, in-hospital mortality was 
more likely to be associated with patient clinical status 
and medical treatment strategy than a history of DM in 
Table 4. Independent predictors of in-hospital and 1-year mortality in patients with acute myocardial infarction who 
underwent successful percutaneous coronary intervention
     HR 95% CI p value
In-hospital mortality
Killip class IV vs. class I 4.568  2.178-9.579 < 0.001
ACE inhibitor or ARB 0.215  0.121-0.383 < 0.001
Left ventricular ejection fraction, % 0.918   0.897-0.938 < 0.001
Creatinine clearance, mL/min 0.964   0.951-0.978 < 0.001
Killip class III vs. class I 2.558   1.276-5.129 0.008
ST elevation MI vs. non-ST elevation MI 1.894 1.029-3.487 0.040
History of diabetes mellitus 1.381 0.799-2.387 0.248
One-year mortality
Killip class IV vs. class I 3.477   1.924-6.285 < 0.001
Age, yr 1.057 1.033-1.081 < 0.001
Left ventricular ejection fraction, % 0.960 0.945-0.974 < 0.001
Killip class III vs. class I 2.312 1.400-3.817 0.001
Creatinine clearance, mL/min 0.983   0.974-0.993 0.001
Balloon angioplasty vs. Cypher  2.979 1.409-6.296 0.004
Bare metal stents vs. Cypher  2.165  1.166-4.019 0.014
Multi-vessel disease 1.686  1.103-2.578 0.016
Female gender 1.617  1.057-2.475 0.027
Current smoker 1.560  1.037-2.346 0.033
History of diabetes mellitus 1.504   1.032-2.191 0.034
HR, hazard ratio; CI, confidence interval; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; MI, myocardial 
infarction.Park KH, et al. Impact of DM on mortality in AMI   187
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patients with AMI who underwent successful PCI. 
DM is a well-known metabolic abnormality of hy-
perglycemia and insulin resistance, and a variety of 
mechanisms, including endothelial dysfunction, abnor-
mal platelet function, and coagulation abnormalities, 
are responsible for accelerated atherosclerosis and ex-
cessive neointimal formation after coronary interven-
tion [16-18]. DM is associated with an increased risk of 
death, stent thrombosis, and restenosis after PCI [19-
21]. Our results showed that DM was an independent 
predictor of 1-year mortality in patients with AMI. Al-
though patients received successful revascularization 
and improved management, patients with DM still had 
high 1-year mortality rates. Patients with DM had more 
depressed left ventricular systolic function, decreased 
renal function, and an increased prevalence of three-
vessel disease or left main coronary artery disease. 
Therefore, patients with DM tended to receive incom-
plete revascularization. These poor clinical conditions 
and incomplete revascularization could also affect the 
high incidence of 1-year mortality and MACE in patients 
with DM [22]. Our results showed that repeated PCI 
tended to be more frequent in patients with DM dur-
ing the 1-year follow-up period. The major stimulus for 
increased intimal hyperplasia in patients with DM may 
be hyperinsulinemia, as supported by the findings of 
several studies [23-26]. Therefore, even though patients 
with AMI and DM underwent successful PCI, they re-
quired further intensive treatment and continuous at-
tention.
The rates of in-hospital mortality and 1-year mortal-
ity were 4.6% and 5.0% in the patients with AMI and 
DM after successful revascularization. Even if a direct 
comparison is impossible, these rates are relatively low 
compared to those of previous studies [8,11,12,27,28]. 
While patients with DM still have high mortality rates, 
successful PCI and appropriate medical treatment 
should help to improve their clinical outcomes.
Study limitations
Many limitations of our study should be noted. First, 
this was a multicenter prospective observational regis-
try study and not a randomized controlled trial. Second, 
we only included patients with AMI who underwent 
successful revascularization and excluded those who 
received medical treatment including thrombolytic 
therapy. Therefore, we could not evaluate the impact of 
DM in patients with AMI. Third, because a follow-up 
coronary angiography was performed in only approxi-
mately 43% of all patients, we may have underestimated 
the incidence of repeated PCI and MACE.
In conclusions, DM was more highly associated with 
1-year mortality than in-hospital mortality in patients 
with AMI who underwent successful PCI. This suggests 
that patients with AMI and DM who undergo successful 
PCI may require further intensive treatment and con-
tinuous attention.
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